XNAS · RIGL
+0.96% · +$0.4500 · Vol 164.8K
Market closed · last close 4:00 PM ET · price as of 16:01:08 ET
Rigel Pharmaceuticals Inc. (New)

Rigel Pharmaceuticals Inc. (New)

PHARMACEUTICAL PREPARATIONS
$47.09
Card
Relationship Map

Follow $RIGL

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $RIGL by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Analyst data unavailable at compute time
RIGL
Rigel Pharmaceuticals Inc. (New)
Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

77/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is RIGL moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading RIGL catalysts
About Rigel Pharmaceuticals Inc. (New)
PHARMACEUTICAL PREPARATIONS
Listed since
2000
Employees
174
Country
US

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$47.13
Day high
$47.51
Day low
$46.49
Previous close
$46.64
52W high
$50.96
-7.59% from high
52W low
$25.44
85% of range
Market cap
$871.2M
P/E
7.77×
EPS
$6.06
Beta
0.64
Shares out
18.7M
Volume
164.8K
0.57× rel vol
Avg volume
288.9K
VWAP
$46.91
Price history computed in-house
1W
+6.15%
1M
+2.61%
3M
+28.84%
1Y
+36.69%
YTD
+9.95%
SMA 50 $43.00 · above
SMA 200 $36.35 · above
52W position 85%

RIGL overview

Veridion Score
77
Registered · 2026-09-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around RIGL.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading RIGL Form 4 filings
Public disclosures

Congress activity in RIGL

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for RIGL in the cached public ledger.

Federal contracts

RIGL contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for RIGL in this window.
Lobbying spend

RIGL lobbying filings, year to date.

Registered lobbying filings matched to Rigel Pharmaceuticals Inc. (New).

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for RIGL in this window.
Loading news for RIGL
Analyst ratings
Sovereign unlock shows live analyst consensus for RIGL.
Options
Sovereign unlock shows live options positioning for RIGL.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.